课题基金 / 基金详情

Population-level impact of direct-acting antiviral (DAA) therapies for chronic hepatitis C on extrahepatic manifestations

Population-level impact of direct-acting antiviral (DAA) therapies for chronic hepatitis C on extrahepatic manifestations
直接作用抗病毒（DAA）治疗慢性丙型肝炎对肝外表现的人群影响
批准号：
375866
负责人：
Rossi Carmine
金额：
$9.83万
依托单位：
B.C. Centre for Disease Control (Vancouver)
依托单位国家：
加拿大
项目类别：
Fellowship Programs
财政年份：
2017
资助国家：
加拿大
项目状态：
已结题
起止时间：
2017-11-01 至 2020-11-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=375866&lang=en
关键词：
Administrative Linkages British Columbia Direct-Acting Antiviral Therapy Epidemiology Extrahepatic Manifestations Hepatitis C Virus Inverse-Probability Of Treatment Weighting Longitudinal Cohort Study Propensity Score Time-To-Event Modeling

项目摘要

项目成果

Rossi Carmine的其他基金

相似基金

相关文献

中文摘要
翻译
丙型肝炎病毒（HCV）感染影响了多达250,000加拿大人。大多数受感染的加拿大人是婴儿潮一代，出生于1945年至1975年之间，并且已经携带HCV数十年。虽然有有效的治疗方法，但摄取率仍然很低，HCV-in
英文摘要
Hepatitis C virus (HCV) infection affects as many as 250,000 Canadians. Most infected Canadians are baby boomers, born between 1945-1975, and have been living with HCV for decades. Although effective treatments are available, uptake remains low and HCV-in
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Impact of chronic hepatitis C virus (HCV) direct-acting antiviral therapy on extrahepatic manifestations among HIV co-infected British Columbians engaged in clinical care
Real-world effectiveness of direct-acting antiviral therapy for chronic hepatitis C among HIV co-infected Canadians receiving clinical care
Rates and Risk Factors for Hepatitis C Re-Infection or Late Relapse after Sustained Virologic Response to Treatment among HIV Co-Infected Canadians
Injection Cocaine Use and Renal Function Decline among Hepatitis C-HIV Co-Infected Canadians Receiving Clinical Care
海外基金